Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials
Authors' conclusion
iGlarLixi is a simple, well-tolerated, once-daily alternative for treatment advancement in older people with T2D that provides significant improvements in glycaemic control without increasing hypoglycaemia risk, thus reducing the treatment burden.
Study context
- Population
- People with T2D advancing or switching from oral agents, a GLP-1 RA or basal insulin, from four LixiLan trials (LixiLan-O, LixiLan-G, LixiLan-L, SoliMix)4 RCTs
- Participants
- 497 vs 1,039
- Comparison
- iGlarLixi in participants aged ≥65 vs <65 years
- ≥65 yearsn = 497
- <65 yearsn = 1,039reference
- Outcome
- Least squares mean HbA1c change from baseline to EOT
- Follow-up
- 26 or 30 weeks
Methodological detailssubgroup analysis by age
- Subgroup analysis by age
Pooled result
As reported in the abstract
| Group | Value | Change in % |
|---|---|---|
| <65 years | least squares mean −14.32 (95% CI −14.97–-13.77) mmol/mol | −1.31% |
| ≥65 years | least squares mean −13.66 (95% CI −14.54–-12.79) mmol/mol | −1.25% |
Value
<65 yearsleast squares mean −14.32 (95% CI −14.97–-13.77) mmol/mol
≥65 yearsleast squares mean −13.66 (95% CI −14.54–-12.79) mmol/mol
Change in %
<65 years−1.31%
≥65 years−1.25%
Further pooled results
HbA1c <53 mmol/mol (<7%) at EOT
HbA1c <59 mmol/mol (<7.5%) at EOT
HbA1c <64 mmol/mol (<8%) at EOT
Clinically relevant HbA1c reduction without hypoglycaemia
- Clinically relevant HbA1c reduction without hypoglycaemia: >1% from baseline for HbA1c ≥64 mmol/mol [≥8%] or ≥0.5% for HbA1c <64 mmol/mol [<8%]
HbA1c <53 mmol/mol (<7%) at end of treatment (EOT)
- Achievement of HbA1c targets was similar between age groups
Safety
ADA Level 1 hypoglycaemia
Event rate ≥65 years 2.1 events per patient-year · <65 years 1.7 events per patient-year
ADA Level 1 hypoglycaemia
- Incidence and event rate comparable between the two groups
Adverse events
- Adverse events were similar between the two age groups
Original publication
Advancing type 2 diabetes therapy with iGlarLixi in older people: Pooled analysis of four randomized controlled trials. Diabetes Obes Metab. Published 11 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →